TY - JOUR
T1 - Low-density lipoprotein cholesterol
T2 - How low can we go?
AU - Sherbet, Daniel P.
AU - Garg, Puja
AU - Brilakis, Emmanouil S.
AU - Banerjee, Subhash
PY - 2013/8
Y1 - 2013/8
N2 - Elevated low-density lipoprotein cholesterol (LDL-C) is an established cause of cardiovascular disease and subsequent adverse events. The efficacy and safety of lowering plasma LDL-C to reduce the risk of coronary heart disease (CHD) and secondary event rates are now well established. What has not been established, however, is a plasma LDL-C lower threshold level of safety and efficacy. Here we review intensive plasma LDL-C-lowering with statins and argue that even further reductions of plasma LDL-C than current guideline targets is likely to safely reduce cardiovascular event rates. We discuss how to achieve very low levels of plasma LDL-C using both traditional and novel LDL-lowering therapies.
AB - Elevated low-density lipoprotein cholesterol (LDL-C) is an established cause of cardiovascular disease and subsequent adverse events. The efficacy and safety of lowering plasma LDL-C to reduce the risk of coronary heart disease (CHD) and secondary event rates are now well established. What has not been established, however, is a plasma LDL-C lower threshold level of safety and efficacy. Here we review intensive plasma LDL-C-lowering with statins and argue that even further reductions of plasma LDL-C than current guideline targets is likely to safely reduce cardiovascular event rates. We discuss how to achieve very low levels of plasma LDL-C using both traditional and novel LDL-lowering therapies.
UR - http://www.scopus.com/inward/record.url?scp=84880892760&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880892760&partnerID=8YFLogxK
U2 - 10.1007/s40256-013-0013-8
DO - 10.1007/s40256-013-0013-8
M3 - Review article
C2 - 23609530
AN - SCOPUS:84880892760
SN - 1175-3277
VL - 13
SP - 225
EP - 232
JO - American Journal of Cardiovascular Drugs
JF - American Journal of Cardiovascular Drugs
IS - 4
ER -